Pangwakas na Pagsusuri Mula sa Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-state Efficacy at Kaligtasan ng Etranacogene Dezaparvovec sa Mga Matanda na May Malubha o Katamtamang Malubhang Hemophilia B
Mga Highlight Mula sa ika-15 Taunang Kongreso ng EAHAD

Pangwakas na Pagsusuri Mula sa Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-state Efficacy at Kaligtasan ng Etranacogene Dezaparvovec sa Mga Matanda na May Malubha o Katamtamang Malubhang Hemophilia B

Wolfgang Miesbach1; Frank WGLeebeek2; Michael Recht3; Nigel S. Susi4; Susan Lattimore3; Giancarlo Castaman5; Michiel Coppens6; David Cooper7; Sergio Slawka7; Stephanie Verweij7; Robert Gut7; Ricardo Dolmetsch7; Yanyan Li8; Paul E. Monahan8; Steven W. Pipe9

HOPE-B Mga Imbestigador1; University Hospital Frankfurt, Frankfurt, Alemanya2; Erasmus MC, University Medical Center Rotterdam, Netherlands3; Oregon Health & Science University, Portland, OR, United States4; Unibersidad ng North Carolina, Chapel Hill, NC, Estados Unidos5; Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy6; Mga Sentro ng Medikal ng Unibersidad ng Amsterdam, Unibersidad ng Amsterdam, Amsterdam, Netherlands7; uniQureBV, Amsterdam, Netherlands/uniQure Inc. Lexington, MA, USA8; CSL Behring, Hari ng Prussia, PA, United States9; Unibersidad ng Michigan, Ann Arbor, MI, Estados Unidos

KAUGNAY NA NILALAMAN

Mga Interactive na Webinar
Imahen

Please enable the javascript to submit this form

Sinusuportahan ng mga grant na pang-edukasyon mula sa Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, at uniQure, Inc.

Mahalagang SSL